HCV NS5B RNA-dependent RNA polymerase — Drug Target

All drugs that target HCV NS5B RNA-dependent RNA polymerase — marketed and clinical-stage. Includes 5 drug classes acting on this target.

Drug classes

Nucleotide analog NS5B polymerase inhibitor · Direct-acting antiviral combination (nucleotide + non-nucleoside polymerase inhibitor) · NS5B polymerase inhibitor · HCV NS5B polymerase inhibitor · Non-nucleoside NS5B polymerase inhibitor

Marketed (2)

• Sofosbuvir Oral Product · MTI University · Nucleotide analog NS5B polymerase inhibitor · Virology / Hepatology
  Sofosbuvir is a nucleotide analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.
• Epclusa (SOF/VEL) · University of California, San Francisco · Direct-acting antiviral combination (nucleotide + non-nucleoside polymerase inhibitor) · Infectious Disease / Virology
  Epclusa combines a nucleotide polymerase inhibitor (sofosbuvir) and a non-nucleoside polymerase inhibitor (velpatasvir) to block hepatitis C virus replication.

Phase 3 pipeline (3)

• DCV · Bristol-Myers Squibb · NS5B polymerase inhibitor · Virology / Hepatology
  DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication.
• ME-609 · Medivir · HCV NS5B polymerase inhibitor · Virology/Infectious Disease
  ME-609 is a hepatitis C virus (HCV) NS5B polymerase inhibitor that blocks viral RNA replication.
• ABT-333 · AbbVie (prior sponsor, Abbott) · Non-nucleoside NS5B polymerase inhibitor · Virology / Hepatology
  ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.